To determine whether the addition of lisofylline (LSF) to idarubicin (12 mg/m 2 daily × 3) + ara-C (1.5 g/m 2 daily × 4) affects the rates of infection, serious infection, CR or mortality during remission induction of newly diagnosed AML, RAEB-t or RAEB, we randomized 70 patients to 3 mg/kg lisofylline or placebo every 6 h i.v., to begin 6 h before the first dose of idarubicin and to continue until recovery of neutrophil and platelet counts or for 28 days, whichever came first. Eligibility required that patients be below age 71 years, have no history of abnormal counts, or chemotherapy for a prior malignancy, and have a creatinine Ͻ1.6 mg/dl and bilirubin Ͻ3.0 mg/dl. The study was double-blinded and infections were tabulated separately and independently at MD Anderson and by a three-member outside panel of experts. Logistic regression was used to assess the relative effects of treatment arm (LSF or placebo), age, performance status, treatment site (laminar air flow room or not), and cytogenetics on rates of infection and serious infection following the first course of chemotherapy, and on CR rate. There were 84% and 87% concordance between the expert panel and MD Anderson enumerations of infection and serious infections, respectively. Both analyses found no significant (P Ͻ 0.05) differences between the rates of infection, or serious infection, in the placebo and LSF groups. CR, 60-day, and overall mortality rates were similar in the two groups, as were time to neutrophil and blood count recovery and outcome once in CR. Logistic regression analyses supported the above conclusions. Severe nausea/vomiting and mucositis were more frequent in the LSF group. Our results suggest that larger studies of LSF in newly diagnosed AML, RAEB-t, or RAEB are not warranted.
Introduction
Attempts at decreasing the infection rate in patients with acute myeloid leukemia (AML) have generally focused on use of prophylactic antibiotics and/or various isolation techniques, eg treatment in a laminar air flow room. Under the assumption that invasion of the bloodstream by microorganisms results from breakdown of barriers between the blood and such organs as the gut or skin, another method to prevent infections involves use of agents that might maintain the integrity of such barriers. By stabilizing the alveolar-capillary membrane, these agents might also lessen the severity of the 'adult respiratory distress syndrome,' a frequently fatal sequel to major infections, in particular sepsis or pneumonia.
Lisofylline is a newly-developed drug that is believed to affect intracellular 'signaling pathways,' especially those involving cytokines, so as to maintain barrier integrity after insults such as chemotherapy. 1 Support for this belief comes from results of a randomized trial involving 60 patients receiving allogeneic marrow transplants from HLA-identical siblings. 2 Randomization was either to placebo, lisofylline at 2 mg/kg/day, or lisofylline at 3 mg/kg/day. During the 5 weeks immediately following transplant patients receiving lisofylline at 3 (but not 2) mg/kg/day had statistically significant decreases in the rates of bacterial and fungal infection, as well as in the rate of serious infections (eg those associated with hypotension or organ involvement). There was no difference in the rate of neutrophil recovery between the 3 mg/kg, 2 mg/kg, and placebo groups, leading to speculation that the effects of lisofylline at 3 mg/kg reflected barrier protection. Such barrier protection might have been responsible for the lower mortality rate, as assessed 100 days after transplant, in the 3 mg/kg group. These results led to the trial reported here.
Patients and methods
Eligibility for the trial required a diagnosis of de novo newly diagnosed AML, de novo newly diagnosed refractory anemia with excess blasts (RAEB), or de novo newly diagnosed RAEB 'in transformation' (RAEB-t). Additionally, patients had to be under age 71 years, had to have serum creatinine and bilirubin below 1.6 and 3.0 mg/dl, respectively, and could not have an antecedent hematologic disorder, defined as more than a 1 month history of a documented abnormality in blood count. Patients with acute promyelocytic leukemia were ineligible.
The trial began on 2 May 1995 with the last patient registered on 19 March 1997. Between these two dates, 81 patients meeting the eligibility criteria described above received treatment for AML, RAEB-t or RAEB at MD Anderson. Seventy of the 81 went on the lisofylline study. Nine did not participate because of physician choice and two because of patient choice. None of these 11 had risk factors excluding them from the trial. Indeed, the 70 patients who went on study and the 11 who did not were similar with respect to age, performance status, cytogenetics and infection status at the start of treatment, and subsequently had similar survival, disease-free survival and CR rates.
After stratification for age (below or above 65 years) and diagnosis (AML vs RAEB-t or RAEB), the 70 patients were randomly assigned to receive induction chemotherapy accompanied by either lisofylline or placebo. Both patients and MDA physicians were unaware of the specific assignment. Induction chemotherapy was idarubicin 12 mg/m 2 intravenously over 0.5 h daily on days, 1, 2 and 3 and cytosine arabinoside (ara-C) 1.5 g/m 2 daily for 4 days (1-4) by continuous i.v. infusion. Lisofylline or placebo (both supplied by Cell Therapeutics, Seattle WA, USA) 3 mg/kg i.v. every 6 h began 6 h before the first dose of idarubicin and continued until recovery of the neutrophil count to Ͼ10 3 /l and platelet count to Ͼ10 5 /l or for 28 days, whichever came first. Patients whose bone marrows showed persistence of blasts received a second course identical to the first beginning a median of 30 days (range 15-52 days) after the start of course one, with lisofylline or placebo (whichever had been given on course one) administered on the second course as described for course one. Patients not in remission (CR: marrow with Ͻ5% blasts, platelet count above 10 5 /l and neutrophil count above 10 3 /l) after a second course were removed from the study. Once in CR patients were given one course of ara-C (100 mg/m 2 daily × 5 days by continuous infusion) alternating with one course of idarubicin (8 mg/m 2 daily days 1, 2) + ara-C (1.5 g/m 2 daily days 1-2 by continuous i.v. infusion) every 4-5 weeks for 1 year from CR date.
Because acquisition of infection was the principal study endpoint, supportive care practices are particularly noteworthy. As previously, we treated patients above age 49 years in laminar air flow rooms (PE) whenever such rooms were available. 3 Patients who presented with, or developed, fever and/or infection were given intravenous ceftazidine plus vancomycin. Ninety-three per cent of the patients who had neither fever nor infection when treatment began received antibacterial prophylaxis, most often with oral trimethoprim/sulfamethoxazole (one double strength tablet twice daily), less often with ciprofloxacin or ceftazidime, one of the latter two drugs having originally been administered for an infection that had resolved when chemotherapy began. Ciprofloxacin or ceftazidime were then continued after chemotherapy started. Eighty-nine percent of patients received antifungal prophylaxis, usually oral fluconazole (200 mg twice daily) + itraconazole (200 mg twice daily). One patient received amphotericin on day 1 of therapy because of pneumonia. Otherwise patients began amphotericin if fever persisted for 3 days despite use of anti-bacterial antibiotics. One patient in each group received granulocyte transfusions. Patients were not given G-or GM-CSF unless infection occurred.
Analysis of infections during and after the first course of therapy was done at MD Anderson and, separately and independently, by a panel of experts (G Bodey retired from MD Anderson, Houston, TX; J Wade, Fred Hutchinson Cancer Center, Seattle, WA; W Hughes, St Judes Hospital, Memphis, TN). Panel members were unaware of whether patients had received lisofylline or placebo. The panel enumerated 'neutropenia-related infections,' with neutropenia defined as the interval from the start of induction chemotherapy to the 7th consecutive day when the absolute neutrophil count was Ͼ500/l. Neutropenia-related infections were divided into 'microbiologically documented' and 'clinically documented'. The former were those in which a bacterial or fungal pathogen was cultured from blood or a normally sterile site, or was identified histologically. For coagulase-negative staphylococcus, non-JK corynebacteria, or other generally saprophytic skin organisms at least two positive blood cultures within a 24 h period were required. Clinically documented infections were either culture-negative septic shock, or culture-negative pneumonia. Clinically documented infections were defined as 'serious,' as were those microbiologically documented infections involving organs, producing hypotension refractory to volume replacement, or in which cultures remained positive despite appropriate treatment. The MD Anderson definitions differ from those used above in that serious infections include only pneumonia and/or documented fungal infection.
Statistical methods
The principal study endpoint was the incidence of neutropenia-related infection (defined above) in the LSF and placebo arms. Secondary endpoints were incidence of serious neutropenia-related infection and of CR. Based on an expected rate of neutropenia-related infection of 50% in the placebo group, the study, with 35 patients per arm, had 77% power to detect a decrease in this rate to 20% in the LSF group, assuming a two-sided test with significance level 0.05. Other outcomes examined were survival, disease-free survival (DFS) and remission duration. For the DFS analysis patients were said to have had an event if they died, relapsed or failed to enter CR, with failure always considered to have occurred on day 1. For the remission duration analysis the event was relapse. Patients who had not had an event were censored at time of last follow-up, or, for the remission duration analysis, death in CR. Survival, DFS, and remission duration were compared between treatment groups using the log rank test.
Association between categorical variables, including imbalance of patient characteristics between treatment groups, was assessed using Fisher's exact test or its generalizations. 4 Agreement between expert panel and MD Anderson ratings of infection within each treatment group was assessed by kappa statistics. The Wilcoxon-Mann-Whitney test was used to compare numerical variables between treatment groups. Because randomized studies of the size reported here do not guarantee that the two treatment groups will be similar with respect to important non-treatment-related variables, logistic regression 5 was used to adjust for patient characteristics while determining the effect of treatment with lisofylline vs treatment with placebo on acquisition of neutropenia-related infections and serious neutropenia-related infections following the first course of chemotherapy, and on CR rate. For each of these three outcomes, a multivariate logistic model was obtained by performing a backward elimination with P value cutoff 0.05, allowing any variable previously deleted to reenter the final model at P = 0.05. Goodness-of-fit was assessed using partial residual plots, 6 smoothed by the lowess method. Results Table 1 compares the characteristics of the 35 patients randomly assigned to receive placebo with those of the 35 assigned to lisofylline. All 70 patients had de novo AML, de novo RAEB-t, or de novo RAEB. Given that the median age of patients with newly diagnosed AML is close to 65 years, our patients were relatively young. Regarding other pretreatment variables that might be expected to affect likelihood of infection following treatment, a similar proportion of placebo and lisofylline-treated patients were chiefly or totally bedridden (Zubrod PSϾ2), were treated in laminar air flow rooms, had an FUO or infection at the start of therapy, and received antibacterial and antifungal prophylaxis. More placebo-treated patients had a normal karyotype, reflecting a preponderance of lisofylline-treated patients with prognostically unfavorable karyotypes ('other' in Table 1 ). Six placebo-treated patients had monosomy of chromosomes 5 and/or 7 or deletions of the long arms of these chromosomes vs 10 lisofylline-treated patients (P = 0.29).
The expert panel and MD Anderson assessments showed a high level of agreement for infection (estimated concordance Kappa = 0.71 for placebo, 0.76 for lisofylline, 87% overall agreement) and also for 'serious' infection (Kappa = 0.56 for placebo, 0.60 for lisofylline, 84.3% overall agreement). Table 2A examines the acquisition of 'neutropenic infections'. Patients given placebo and patients given lisofylline had similar rates of infection: 17/35 placebo and 13/35 lisofylline (P = 0.46) as judged by the expert panel, 18/35 placebo and 15/35 lisofylline (P = 0.63) as judged by MD Anderson. There was also no significant difference between the two groups in total number of infections (P = 0.84, Table 2B ). The days at risk for developing a course one infection, ie days until either CR, death, start of course two or removal from study, were similar in the placebo and lisofylline groups (P = 0.41 with respective medians of 29 and 28 days). Nine of the 17 or 18 patients with infection (17 expert panel evaluation, 18 MD Anderson evaluation) in the placebo group received G-CSF when infection was documented. The corresponding figure in the lisofylline group was 4/13-15. Of course, it remains to be proven that administration of CSFs will influence mortality rates in infected patients. Although the study's primary endpoint was incidence of infection, a secondary endpoint was incidence of 'serious' infection. Both the expert and MD Anderson assessments noted that fewer patients had serious infection in the lisofylline group (Table 3A) and that there were also fewer serious infections in this group (Table 3B ). The P value for the comparison of the number of patients developing serious infection in the two arms was 0.11 based on the MD Anderson analysis and 0.17 based on the expert panel analysis. Table 4 is a tabulation of the infections in the two groups (MD Anderson analysis). In the placebo group, seven patients (denoted by asterisks in Table 4 ) had 'definite' fungal (± bacterial) infections (aspergillus three, fusarium one, Candida krusei one, Candida tropicalis one, Candida tropicalis Candida albicans one, ie infections in which the fungus was either seen in tissue or grown from blood or broncheoalveolar lavage fluid. Four proved fatal. In the lisofylline group two patients had 'probable' torula infections, both cases of fatal pneumonia in which torula was grown from sputum. The P value for the LSF-placebo difference in patients acquiring definite + probable fungal infections was 0.15. The expert panel felt that five patients in the placebo group had developed fungal infection (excluding one patient with aspergillus seen at autopsy in the belief that the pneumonia might have been present prior to treatment and one with fusarium seen in a leg biopsy specimen simultaneously with the onset of pneumonia) and that no patients in the lisofylline group had developed fungal infection (thus excluding the two cases MD Anderson considered 'probable'). Using this assessment the P value for the difference between the two groups was 0.054. Both the expert panel and MD Anderson concluded that there was no difference in the incidence of culturenegative pneumonia between placebo and lisofylline groups.
It is well-known that autopsies are often required to recog- a The number of patients in the column totals 37 because one patient with 'sepsis alone' had a separate episode of pneumonia as did one with a local fungal infection. b The number of patients in the column totals 38 because three patients with 'sepsis alone' also had separate episodes of pneumonia. *The asterisks identify patients considered to have definite, rather than probable, fungal infection.
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nize fungi as pathogens. Seven placebo-treated and six lisofylline-treated patients died within 60 days of beginning treatment. Autopsies were obtained in five of the placebo but none of the lisofylline patients. The fungal etiology of an infection was discovered in one placebo-treated patient. Excluding autopsy data leave the expert panel fungal assessment exactly as noted above while changing the MD. Anderson assessment as follows: P value for comparison of number of patients with probable or definite fungal infection = 0.26. CR rates were 74% in the placebo group and 77% in the lisofylline group. Forty-eight of the 53 CRs (91%) were seen after the first course of therapy and rates of CR after the first course were 74% for placebo, 63% for lisofylline (P = 0.44). Neither time to a neutrophil count Ͼ1000/l (medians 25 days placebo, 28 days lisofylline) nor time to a platelet count Ͼ100 000/l (medians 26 days placebo, 25 days lisofylline) differed in patients achieving CR in one course in the two groups (P = 0.49 for neutrophils, P = 0.48 for platelets). Mortality rates within the first 60 days were also very similar in the two groups (7/35 placebo, 6/35 lisofylline). Overall survival was essentially identical in the placebo and lisofylline groups (P = 0.92) with a median for all patients of 56 weeks and with a median follow-up of 60 weeks in the patients who are currently alive. These similarities also applied to diseasefree survival once in CR (P = 0.52) and to remission duration (P = 0.29), which had a median of 42 weeks for all patients. Logistic regression analyses were done using the MD Anderson assessments of infection and serious infection. The only variable tending to be predictive of acquisition of serious infection was treatment arm (P = 0.058, lisofylline favorable). None of the variables examined predicted acquisition of infection (serious or minor). Independent predictors of CR were age (older = unfavorable, P = 0.040), cytogenetics (not inv(16), t(8;21) or normal = unfavorable, P = 0.048), development of any infection (unfavorable, P = 0.002), and development of serious infection (unfavorable, P = 0.057). Thus, although serious infection showed a possible trend to be associated with a lower CR rate and treatment with lisofylline a possible trend to be associated with a lower serious infection rate, treatment with lisofylline was not associated with a higher CR rate. The failure of lisofylline to produce higher CR rates may be explained by examining Table 5 . Although, as seen in Table  5 , the lisofylline group had seven fewer severe infections, and the CR rates among patients with severe infections were virtually identical in the two treatment groups (6/13, 46%, placebo vs 3/6, 50%, lisofylline), this was counterbalanced by 854 the slightly lower CR rate among patients without severe infection in the lisofylline group (24/29 = 83% CRs in lisofylline patients without serious infection vs 20/22 = 91% CRs in placebo patients without serious infection). When judged using standard United States NCI criteria, more patients in the lisofylline group had severe nausea and mucositis (Table 6 ). Another way of assessing toxicity is to examine how frequently placebo or lisofylline were prematurely discontinued, ie before CR had occurred, or 28 days had elapsed from start of treatment. Premature discontinuation presumably reflects physician or patient judgement that the treatment should not be continued. On course one this occurred in eight lisofylline patients (23%) and six placebo patients (17%). The lisofylline patients were removed a median of 17 days prematurely while the corresponding figure was 18 days for placebo patients. As noted above, patients not in CR after course one were again scheduled to receive lisofylline or placebo (whichever was given on course one) on course two. Seven patients in the lisofylline group and four in the placebo group received a second course of idarubicin + ara-C. Four of the former and three of the latter received study drug (lisofylline or placebo) on course 2.
Discussion
The purpose of this study was to see if List et al's 2 results, obtained in patients undergoing allogeneic transplantation and summarized in the Introduction, might also hold true in patients given remission induction chemotherapy for newly diagnosed AML (or RAEB or RAEB-t, which we regard as operationally identical to AML). 3 Unlike List et al we found nothing to suggest either a difference in infection rate between the placebo and lisofylline groups (Table 2) or a difference in mortality. The discrepancies between our results and List et al's could conceivably reflect the higher underlying rates of infection in our patients (about 50% in our placebo group vs 33% in List et al's) . In turn, this difference could have resulted from the older age of our patients, or the differences in anti-leukemia regimens. The data did suggest a possible trend toward reduction in the incidence of serious infection in the LSF group, since the comparative test based on a logistic regression, was marginally significant (P = 0.058). Even if such P values are regarded as interesting it must be pointed out that similar P values were obtained with respect to possible differences in severe mucositis and nausea/vomiting between LSF and placebo. Here, however, the P values (0.08) (nausea/vomiting) and 0.04 (mucositis) were in favor of placebo.
Based on our results, we do not believe that LSF should be compared to placebo in a larger study. Not only is the possibility of a difference in favor of LSF with respect to acquisition of serious infection counterbalanced by the equally plausible possibility of similar differences in favor of placebo with respect to severe nausea/vomiting and mucositis, but, most importantly, CR and induction mortality rates were essentially identical in the placebo and LSF groups. The CR rate after treatment of 35 patients with LSF was 77%. Were a CR rate of 90% required to consider LSF worthwhile, an additional 90 patients would need to receive LSF and a 95% CR rate observed in order to reach the overall 90% CR rate. The low likelihood of this scenario contributed in part to our decision to forego further investigation of LSF.
